Every 10-Q that Si-Bone (SIBN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SIBN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SIBN filings page.
SI-BONE reported higher revenue and a smaller loss for the quarter ended June 30, 2026. Revenue was $56.0 million, up from $48.6 million a year earlier, driven primarily by a $6.8 million increase in U.S. revenue and a 14.9% increase in procedure volumes. Gross margin was 79.5%, compared with 79.8% a year earlier, with the company citing product mix.
For the first six months of 2026, revenue was $108.6 million, up 13.2% from $95.9 million, while net loss was $8.4 million, compared with $12.7 million. Operating cash use was $1.6 million, compared with $4.7 million in the prior-year period. Cash and marketable securities were $145.9 million as of June 30, 2026, and outstanding debt was $35.6 million.
The company said over 150,000 procedures had been performed using its technologies since initial commercialization. It also entered a 102-month San Jose office lease covering 50,485 square feet, with monthly base rent of $128,737 after the first six months and up to $3.8 million of landlord reimbursement for qualifying tenant improvements.
SI-BONE (SIBN) reported Q3 2025 results with strong top-line growth and improved profitability trends. Revenue was $48,656,000, up 20.6% from $40,340,000, driven largely by higher U.S. case volumes. Gross margin expanded to 79.8% from 79.1%, lifting gross profit to $38,846,000.
Operating expenses rose to $44,229,000, primarily from higher sales and marketing and general and administrative costs, resulting in a smaller operating loss of $5,383,000 versus $7,633,000 a year ago. Net loss narrowed to $4,566,000 compared with $6,575,000, and net loss per share improved to $0.11 from $0.16.
Liquidity remained solid with cash and cash equivalents of $26,487,000 and short-term investments of $119,257,000. Inventory increased to $35,727,000 to support demand. Long-term borrowings were $35,540,000. Shares outstanding were 43,391,254 as of November 4, 2025.